Alcyone Therapeutics Appoints Dr. Riedel as Chairman and Dr. Meyer as CSO and R&D Head

Alcyone Therapeutics, a clinical-stage biotech firm focused on pioneering cutting-edge genetic therapies for complex neurological disorders, has announced significant new additions to its leadership team. Dr. Norbert Riedel has been appointed as the Chairman of the Board of Directors, while Dr. Kathrin Meyer joins as the Chief Scientific Officer and Head of Research & Development (R&D).

Dr. Riedel, a distinguished biopharmaceutical executive, expressed his enthusiasm for joining Alcyone Therapeutics. He highlighted the company's innovative genetic therapies targeting the central nervous system (CNS) and the promising clinical outcomes achieved with its proprietary intrathecal drug delivery platform. According to Dr. Riedel, these developments have the potential to address substantial unmet needs in the treatment of various neurological conditions.

Dr. Meyer, known for her expertise in genetic therapies for CNS disorders, also expressed excitement about her new role. She emphasized the importance of combining precise biological mechanisms and effective CNS delivery systems. She believes that Alcyone's approach, which merges optimized delivery and advanced gene expression technology, could revolutionize patient care by providing safer and more effective treatments for neurological diseases.

The CEO of Alcyone Therapeutics, PJ Anand, praised the new appointments, noting that Drs. Riedel and Meyer bring exceptional expertise and extensive networks to the company. He highlighted their proven track records in developing life-changing therapies and building innovative biotech companies. Anand is confident that their contributions will significantly boost Alcyone's growth as it advances its precision genetic therapies for X-linked diseases, including a new therapy for Rett Syndrome.

Dr. Riedel's extensive experience includes leadership roles in major healthcare and biotechnology firms. He has served as President and CEO of Aptinyx Inc. and Naurex, which was acquired by Allergan. He also held the position of corporate Vice President and Chief Science and Innovation Officer at Baxter International. Dr. Riedel obtained his Ph.D. and Diploma in Biochemistry from the University of Frankfurt and sits on the boards of several pharmaceutical companies and biotechnology organizations.

Dr. Meyer brings a wealth of experience in the research and clinical development of CNS therapies. Prior to joining Alcyone, she was a Principal Investigator at Nationwide Children's Hospital and an Assistant Professor at The Ohio State University. Her work has been instrumental in the first-in-human translation of several genetic therapies, including treatments for Zolgensma®, Batten's disease, Spinal Muscular Atrophy, and Charcot Marie Tooth type 2. Dr. Meyer holds a Ph.D. in molecular and cellular biology from the University of Bern and is a co-inventor of Alcyone's miREX™ microRNA gene expression platform, which focuses on Rett Syndrome and other X-linked disorders.

Alcyone Therapeutics is dedicated to developing next-generation precision gene-based therapies for neurological conditions. The company's innovative approach integrates advancements in neuroscience with precision dosing platforms to deliver transformative treatments. Alcyone's Falcon™ intrathecal precision dosing and biodistribution platform leverages extensive knowledge of cerebrospinal fluid dynamics, computational modeling, and bioengineering to optimize CNS drug delivery. Additionally, the X-reactivation genetic therapy platform, developed in collaboration with Nationwide Children's Hospital and the University of Virginia, aims to treat X-linked disorders, including Rett Syndrome.

Alcyone has also entered into a license and collaboration agreement with a major biopharmaceutical company to enhance the patient experience and accessibility of neurological antisense oligonucleotide genetic therapies.